Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy
{{output}}
Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed or amplified in biliary tract cancer (BTC). Although NCCN clinical practice guidelines recommend HER2-targeted agents as subsequent-line therapy, drug resistance often restricts the cl... ...
